Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Supernus Pharm (SUPN)

Supernus Pharm (SUPN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,236,553
  • Shares Outstanding, K 52,463
  • Annual Sales, $ 408,900 K
  • Annual Income, $ 110,990 K
  • 60-Month Beta 1.50
  • Price/Sales 3.11
  • Price/Cash Flow 9.87
  • Price/Book 2.28

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate 0.57
  • Number of Estimates 4
  • High Estimate 0.59
  • Low Estimate 0.56
  • Prior Year 0.48
  • Growth Rate Est. (year over year) +18.75%

Price Performance

See More
Period Period Low Period High Performance
1-Month
23.04 +2.30%
on 01/06/20
25.16 -6.32%
on 01/21/20
-0.57 (-2.36%)
since 12/24/19
3-Month
19.35 +21.81%
on 11/06/19
29.36 -19.72%
on 11/05/19
-3.03 (-11.39%)
since 10/24/19
52-Week
19.35 +21.81%
on 11/06/19
43.05 -45.25%
on 02/27/19
-12.51 (-34.67%)
since 01/24/19

Most Recent Stories

More News
Supernus Announces FDA Acceptance for Review of New Drug Application for SPN-812 for the Treatment of ADHD

Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that...

SUPN : 23.57 (-2.64%)
Can Value Investors Pick Supernus Pharmaceuticals (SUPN) Stock?

Is Supernus Pharmaceuticals (SUPN) a great pick from the value investor's perspective right now? Read on to know more.

SUPN : 23.57 (-2.64%)
Supernus to Present at the 2020 J.P. Morgan Healthcare Conference

Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that...

JPM : 133.15 (-2.48%)
SUPN : 23.57 (-2.64%)
Supernus Provides Update on Results from Phase III Study (P301) of SPN-810 for Treatment of Impulsive Aggression (IA) in ADHD Patients

Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, is providing an update...

SUPN : 23.57 (-2.64%)
Look for Shares of Supernus Pharmac to Potentially Pullback after Yesterday's 2.82% Rise

Supernus Pharmac (NASDAQ:SUPN) traded in a range yesterday that spanned from a low of $22.77 to a high of $23.50. Yesterday, the shares gained 2.8%, which took the trading range above the 3-day high...

SUPN : 23.57 (-2.64%)
Supernus to Present at Two November Healthcare Conferences

Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that...

SUPN : 23.57 (-2.64%)
Supernus Submits New Drug Application for SPN-812 for the Treatment of ADHD

Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that...

SUPN : 23.57 (-2.64%)
Shares of Supernus Pharmac Rank the Highest in Terms of Relative Performance in the Pharmaceuticals Industry (SUPN , NKTR , BMY , PCRX , JNJ )

Here are the top 5 stocks in the Pharmaceuticals industry ranked by performance. We compiled the trading activity from yesterday and then analyzed the industry looking for stocks that were outperforming....

BMY : 64.16 (-4.05%)
NKTR : 21.13 (-2.94%)
SUPN : 23.57 (-2.64%)
Watch for Supernus Pharmac to Potentially Rebound After Falling 20.39% Yesterday

Supernus Pharmac (NASDAQ:SUPN) traded in a range yesterday that spanned from a low of $20.01 to a high of $22.00. Yesterday, the shares fell 20.4%, which took the trading range below the 3-day low of...

SUPN : 23.57 (-2.64%)
Intra-Cellular T has the Best Relative Performance in the Pharmaceuticals Industry (ITCI , SUPN , MDCO , PRGO , CTLT )

Below are the top five companies in the Pharmaceuticals industry as measured by relative performance. This analysis was compiled based on yesterday's trading activity as we search for stocks that have...

ITCI : 23.61 (-5.03%)
MDCO : 84.90 (-0.07%)
SUPN : 23.57 (-2.64%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade SUPN with:

Business Summary

Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit...

See More

Key Turning Points

2nd Resistance Point 24.64
1st Resistance Point 24.11
Last Price 23.57
1st Support Level 23.20
2nd Support Level 22.82

See More

52-Week High 43.05
Fibonacci 61.8% 34.00
Fibonacci 50% 31.20
Fibonacci 38.2% 28.40
Last Price 23.57
52-Week Low 19.35

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar